Abiomed to present new data from PROTECT II study in PCI at SCAI meeting

Abiomed Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced that new data from the PROTECT II study will be presented by William O'Neill, M.D., executive dean for clinical affairs at the University of Miami Miller School of Medicine, and principal investigator for the PROTECT II study, during the late-breaking clinical trials session at the Society for Cardiovascular Angiography and Interventions (SCAI) 2011 Scientific Sessions in Baltimore, Maryland.

The presentation, "A Prospective Multicenter Randomized Clinical Trial of Intra-aortic Balloon Pump vs Impella for Hemodynamic Support During High Risk PCI: 90 Day Results from PROTECT II" will be one of four late-breaking clinical trial presentations to be showcased at the meeting. The PROTECT II presentation is scheduled for Friday, May 6 at 12 p.m. ET at the Hilton Baltimore.

PROTECT II was a prospective multicenter randomized clinical trial of Impella versus the intra-aortic balloon pump for hemodynamic support during high risk percutaneous coronary intervention (PCI).

"As the primary association for interventional cardiologists, SCAI represents the core group of clinicians that treat prophylactic and emergent patients with interventional medicine," said Michael R. Minogue, Chairman, President and Chief Executive Officer, Abiomed. "We are excited to present the PROTECT II data to these SCAI members who are devoted to enhancing the standard of care for patients in the cath lab."

SCAI members represent 4,000 adult and congenital interventional cardiologists . Focus areas for SCAI include establishing standards and guidelines for all aspects of cardiac catheterization and angiography, training, credentialing, safety and quality assurance for cardiovascular procedures.

Source: Abiomed, Inc.